Randomized trial demonstrates repair of endothelial injury in a murine model, suggesting a novel treatment for cardiovascular diseases.
Key Points
This research aims to evaluate the effects of CAR-engineered CD34(+) hematopoietic stem/progenitor cells on endothelial injuries in a murine model of thoracic aortic aneurysm and dissection.
Engineered CD34(+) cells using a chimeric antigen receptor targeting VCAM-1 and VEGFA activation domain.
Utilized a lipid nanoparticle system for delivery and expression of CAR in vivo.
Conducted in vitro and in vivo evaluations of cell functions such as differentiation and migration.
Engineered CD34(+) cells restored endothelial function and strengthened cell junctions.
Cells suppressed inflammatory response and blocked disease progression.
Demonstrated effective targeting of injured vascular intima.